Genor Biopharma Receives China Nod for Breast Cancer Drug Trial
Genor Biopharma (HKG:6998) received Chinese regulatory approval to begin human trials of GB268 in breast cancer, according to a Thursday filing with the Hong Kong bourse. The firm plans to conduct a phase 1b/2 clinical trial of the drug in combination based regimens.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.